CVA Family Office’s ARK Genomic Revolution ETF ARKG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
– Sell
-73
Closed -$1.87K – 1292
2024
Q3
$1.87K Hold
73
– – ﹤0.01% 988
2024
Q2
$1.71K Hold
73
– – ﹤0.01% 985
2024
Q1
$2.1K Hold
73
– – ﹤0.01% 929
2023
Q4
$2.4K Buy
+73
New +$1.99K ﹤0.01% 889
2022
Q1
– Sell
-12
Closed -$1K – 947
2021
Q4
$1K Buy
+12
New +$830 ﹤0.01% 866

Other funds holding ARKG

CVA Family Office's ARKG Position: Q4 2024 in Review

CVA Family Office sold out of ARK Genomic Revolution ETF (ARKG) in Q4 2024, closing a stake of 73 shares — an estimated $1.87K sold.

CVA Family Office first reported a position in ARKG in Q4 2021 and held it in 5 quarters. The position peaked at $2.4K in Q4 2023. 241 funds tracked by Wall St. Rank hold ARKG as of Q4 2024.

  • CVA Family Office reported no remaining ARK Genomic Revolution ETF position as of Q4 2024 after selling out during the quarter.
  • CVA Family Office sold 73 ARK Genomic Revolution ETF shares in Q4 2024, an estimated $1.87K.
  • CVA Family Office first reported a position in ARK Genomic Revolution ETF in Q4 2021 and held it in 5 quarters.
  • CVA Family Office's ARK Genomic Revolution ETF position peaked at $2.4K in Q4 2023.
  • 241 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q4 2024.

Based on CVA Family Office's 13F filing for Q4 2024, filed 7 Jan 2025.